Genenta Science

GNTA

Market cap $14.8M

Genenta signs Definitive Agreements with Sophia High Tech Genenta enters aerospace as it continues its strategic transformation into a next-generation ind

MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has entered into a binding offer with Sòphia High Tech S.r.l.

Focused on selective acquisitions of high-quality companies in strategic industrial sectors Focused on selective acquisitions of high-quality companies in strategic industrial sectors

MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that Pierluigi Paracchi, CEO of the Company, has been appointed as a member of the Board of Guarantors of the Italian Academy for Advanced Studies in America, the prestigious center for advanced scholarship hosted at Columbia University in New York, dedicated to promoting Italian culture, research, and intellectual exchange between Italy and the United States.

MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing.

Genenta Science S.p.A. (NASDAQ: GNTA) on Tuesday said it is transitioning to a next-generation strategic industrial consolidator, focusing on acquiring privately held businesses in national-security regulated sectors.

Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies ATC - a Defense-Sector Company: First Industrial Integration Praexidia Foundation Joins as a Long-Term Strategic Shareholder Corporate Name Change to Saentra Forge S.p.A. Biotech Clinical Updates and Partnering Strategy Cash,   Cash Equivalents, and Marketable Securities of approx.

MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi. Over time, Mr.

MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients have been treated with Temferon.

Genenta Science S.p.A. initiating with a Buy rating following a 90% stock surge after announcing a strategic partnership with ANEMOCYTE for LVV plasmid DNA technology. GNTA's lead cell therapy, temferon, has doubled 2-year survival rates in unmethylated MGMT glioblastoma multiforme patients and modestly improved median overall survival. Upcoming data from the phase 1/2a TEM-GU study in metastatic renal cell carcinoma, combining temferon with checkpoint or tyrosine kinase inhibitors, could provide further proof-of-concept.